# Antagonization of Heparin With Protamine Sulfate After TAVI

Study · id `cardio:ct-nct06215378` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06215378](<https://clinicaltrials.gov/study/NCT06215378>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06215378

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 940 participants.

## Technical summary

Registry record NCT06215378. Randomized; single masking; primary purpose treatment. Start 2025-05-25 (actual); primary completion 2027-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 940 participants (planned count; ClinicalTrials.gov record NCT06215378, source copy `cardio:ctgov-nct06215378-2025-08-22`, retrieved 2026-10-26)
- Started: 2025-05-25 (actual) (ClinicalTrials.gov record NCT06215378, source copy `cardio:ctgov-nct06215378-2025-08-22`, retrieved 2026-10-26)
- Primary completion: 2027-03-01 (anticipated) (ClinicalTrials.gov record NCT06215378, source copy `cardio:ctgov-nct06215378-2025-08-22`, retrieved 2026-10-26)
- Completion: 2027-03-01 (anticipated) (ClinicalTrials.gov record NCT06215378, source copy `cardio:ctgov-nct06215378-2025-08-22`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT06215378, source copy `cardio:ctgov-nct06215378-2025-08-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06215378-2025-08-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Antagonization of Heparin With Protamine Sulfate After TAVI
- Acronym: ATLANTIS-Prota
- Condition: Aortic Valve Stenosis
- Condition: Heart Valve Diseases
- Intervention (Drug): Antagonization of heparin with protamine sulfate
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER
- Collaborator: Action Research Group
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)
- Registry lists this organization as a collaborator: Action Research Group (`cardio:org-action-research-group`)

## Provenance

Content hash: f6c4a7240bd6e6b7f2c5782cc8d60dbf236f3c1f7ebf437de4e5b11ceeaf8d2d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
